1. Home
  2. ABBV vs TMUS Comparison

ABBV vs TMUS Comparison

Compare ABBV & TMUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ABBV
  • TMUS
  • Stock Information
  • Founded
  • ABBV 2012
  • TMUS 1994
  • Country
  • ABBV United States
  • TMUS United States
  • Employees
  • ABBV N/A
  • TMUS N/A
  • Industry
  • ABBV Biotechnology: Pharmaceutical Preparations
  • TMUS Telecommunications Equipment
  • Sector
  • ABBV Health Care
  • TMUS Telecommunications
  • Exchange
  • ABBV Nasdaq
  • TMUS Nasdaq
  • Market Cap
  • ABBV 303.1B
  • TMUS 276.5B
  • IPO Year
  • ABBV N/A
  • TMUS N/A
  • Fundamental
  • Price
  • ABBV $175.62
  • TMUS $220.31
  • Analyst Decision
  • ABBV Strong Buy
  • TMUS Strong Buy
  • Analyst Count
  • ABBV 22
  • TMUS 21
  • Target Price
  • ABBV $207.45
  • TMUS $239.65
  • AVG Volume (30 Days)
  • ABBV 6.8M
  • TMUS 4.2M
  • Earning Date
  • ABBV 01-31-2025
  • TMUS 01-23-2025
  • Dividend Yield
  • ABBV 3.74%
  • TMUS 1.60%
  • EPS Growth
  • ABBV N/A
  • TMUS 36.23
  • EPS
  • ABBV 2.87
  • TMUS 8.76
  • Revenue
  • ABBV $55,533,000,000.00
  • TMUS $80,006,000,000.00
  • Revenue This Year
  • ABBV $5.28
  • TMUS $5.08
  • Revenue Next Year
  • ABBV $5.73
  • TMUS $4.84
  • P/E Ratio
  • ABBV $61.18
  • TMUS $25.16
  • Revenue Growth
  • ABBV 0.72
  • TMUS 2.11
  • 52 Week Low
  • ABBV $153.09
  • TMUS $153.84
  • 52 Week High
  • ABBV $207.32
  • TMUS $248.15
  • Technical
  • Relative Strength Index (RSI)
  • ABBV 47.03
  • TMUS 34.78
  • Support Level
  • ABBV $170.34
  • TMUS $217.79
  • Resistance Level
  • ABBV $178.13
  • TMUS $233.33
  • Average True Range (ATR)
  • ABBV 3.59
  • TMUS 4.85
  • MACD
  • ABBV 0.26
  • TMUS -2.90
  • Stochastic Oscillator
  • ABBV 40.68
  • TMUS 8.89

About ABBV AbbVie Inc.

AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics (including Botox).

About TMUS T-Mobile US Inc.

Deutsche Telekom merged its T-Mobile USA unit with prepaid specialist MetroPCS in 2013, and that firm merged with Sprint in 2020, creating the second-largest wireless carrier in the us. T-Mobile now serves 77 million postpaid and 21 million prepaid phone customers, equal to around 30% of the us retail wireless market. The firm entered the fixed-wireless broadband market aggressively in 2021 and now serves more than 5 million residential and business customers. In addition, T-Mobile provides wholesale services to resellers.

Share on Social Networks: